Wereport the fourth case of simultaneous macroamylasemia and macrolipasemia. A 39-year-old womanhad been treated for systemic lupus erythematosus from 1982 to 1993. She was found to have an unexplained increase in serum amylase and lipase activities since 1996. Immunoprecipitation assay showed that amylase was bound to IgA2-k and IgAl-K (IgA2>IgAl), whereas lipase was bound to IgAl-K. During a follow-up period up to December 1999, the patient did not develop any additional autoimmune or lymphoproliferative disorders. In the situation of atypical clinical features associated with hyperamylasemia and hyperlipasemia, the possibility of macroenzymes should be considered.
Introduction
High molecular weight immunoglobulin-bound enzymes (macroenzymes) are not normally cleared by the kidney, and lead to an increase in the corresponding enzymeactivities in the blood. Clinically, it is important to detect macroenzymes, because they frequently interfere with the interpretation of serum enzymeresults, and as a result can cause diagnostic and therapeutic errors (1) . It is knownthat immunoglobulins form complexeswith various serum enzymes,which are routinely measured in clinical laboratories, such as alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, creatine kinase, lactate dehydrogenase, and lipase (1) . To our knowledge, macrolipase has been reported previously in only seven cases (2) (3) (4) (5) (6) (7) (8) . Interestingly, three of those cases also had macroamylase (4, 6, 8) .
Measurement of activities of serum amylase and lipase is an important test for the diagnosis of pancreatitis. Wedescribe a patient with systemic lupus erythematosus (SLE) in remission whohas had high levels of serum amylase and lipase activities, in the absence of any other signs of pancreatitis. We found that the high enzyme activities were due to the presence of different subclasses of IgA complexed with amylase and lipase.
Case Report Patient A 39-year-old woman, who had been treated for SLE with prednisolone at other hospitals from 1982 to 1993, was referred to our hospital for follow-up in June 1998. She was diagnosed as having SLE based on the following clinical manifestations and laboratory findings during the course of disease: malar rash, photosensitivity, arthritis, a positive test for antinuclear antibodies (x320), and a false-positive serologic test for syphilis. She was also diagnosed as having chronic thyroiditis in 1982. Since the degree of hypothyroidism was mild, thyroid hormone replacement had not been required. After the cessation of steroid therapy for SLE, she had been well. Routine blood analysis in 1996 and 1997 showed that amylase and lipase activities were Physical examination revealed no abnormal signs. Laboratory data are summarized in Table 1 . Weconsidered that the patient achieved remission of SLE. The thyroid hormone levels were normal. Amylaseand lipase activities were determined on a Hitachi 7600 automated analyzer with test kits from Daiichi Pure Chemical and KAINOS(Tokyo), respectively. The patient was found to have hyperamylasemia and hyperlipasemia, but no definite findings of pancreatitis were detected by abdominal ultrasonography. the presence of macroamylase. We speculated the possibility that the abnormallipase arose for the samereason as for amylase, and performed immunological analyses as described be- Identification of immunoglohulin-bound amylase and lipase In order to determine whether both serum amylase and lipase were bound to immunoglobulins, we performed an immunoprecipitation assay using antibodies against humanimmunoglobulins. The patient' s serum (50 (il) was incubated with 250 |il of anti-y, anti-a, anti-|i, anti-K, or anti-A, antibody (Dako, Glostrup, Denmark ) at 37°C for one hour. After centrifugation, the supernatant of each sample was concentrated to 50 |il, using Minicon B15 (Amicon, Danvers, MA, USA). Amylase and lipase activities in the samples were measured on a Hitachi 7170 automated analyzer with test kits from Kanto Kagaku (Tokyo) and Wako Pure Chemical (Osaka), respectively. Residual rates were then calculated as the percentage of the enzymeactivities in the samples to those in the serum before immunoprecipitation. Residual rates of both amylase and lipase activities in the patient's serum supernatant were markedly decreased by treatment with anti-oc and anti-K antibodies (Fig. 1) . The results indicated that the two enzymes were bound to IgA-K. Wefurther examined the IgA subclasses, which made up the complexes with each enzyme. Immunoprecipitation assay using antibodies against human IgAl and IgA2 (The Binding Site, Birmingham, UK) was performed as described above. The results showed that residual rates of amylase activities in the patient's serum supernatant were markedly decreased by treatment with anti-IgA2 antibody, and that treatment with antiIgAl antibody had less of an effect (Fig. 2) . In contrast, the residual rate of lipase activity in the patient's serum supernatant was markedly decreased by treatment only with anti-IgA l antibody (Fig. 2) . From these results, we concluded that amylase was bound to IgA2-K and IgAl-K (IgA2-K>IgAl-K), whereas lipase was bound to IgAl-K.
Discussion
Wereport a case of SLEin remission associated with simultaneous macroamylasemiaand macrolipasemia. This case fulfilled the five criteria for the diagnosis of SLE (9) as described above. After treatment with steroid for more than 10 years, the patient achieved remission of the disease. To our knowledge, the simultaneous presence of these macroenzymesin the same patient has been previously reported in only three cases. Pancreatitis or renal failure is usually considered as the cause of hyperamylasemiaand hyperlipasemia. In situations of atypical clinical features, determination of the amylase-creatinine clearance ratio is helpful in identifying macroamylase: this ratio is less than 1% for most patients having macroamylase (1).
In general, the presence of an immunoglobulin-bound macroenzymein a patient is regarded as a benign phenomenon that does not require any special treatment. Nevertheless, clinicians must consider an increased risk for developing an autoimmune or lymphoproliferative disorder in patients, in whom the light-chain restriction in immunoglobulin-enzyme complexes is observed as in the present patient (1). Fortunately, our patient did not develop such a disorder during a follow-up period for SLE. In addition, no correlation was found between the presence of macroenzymesand the activity of SLE. If a patient with unrecognized presence of macroamylase and macrolipase experiences an episode of acute abdomenand these enzymesare measured, the activities of both serum enzymes would be high. This can cause unnecessary diagnostic and therapeutic efforts. Indeed, Gullo et al (10) Therefore, if these macroenzymes are identified in a patient, it is important to communicatethe information to the physician who is caring for the patient and to educate the patient on the clinical significance of these macroenzymes.
Clinical backgrounds and linked immunoglobulins in the reported cases with simultaneous macroamylasemiaand macrolipasemia and in the present case are summarized in Table  2 . Since the underlying diseases were different, the simultaneous presence of these macroenzymesis unlikely to be a specific diagnostic marker for any particular disorder. Regarding the linked immunoglobulins, IgA was involved in all the cases. Light-chain restriction was demonstrated in two cases including our case. HumanIgA occurs as two subclasses, IgAl and IgA2, and differences occur in their distribution in serum and in various external secretions (ll) . For example, 90% to 95% of serum IgA is of the IgAl subclass. On the other hand, external secretions contain 50% to 70% IgAl and 30% to 50% IgA2. We analyzed IgA subclasses involved in the formation of complexes with the two enzymes in our case. Interestingly, amylase was mainly bound to IgA2-K, whereas lipase was bound only to IgAl-K. This is the first case of the simultaneous presence of macroamylaseand macrolipase, in which each macroenzyme was shown to be complexed with different subclasses of IgA. Although the mechanism for the formation of immunoglobulin-bound macroenzymes is still unknown, there is a restriction of immunoglobulin classes that makeup the complexes. In the cases with macroamylasemia, the linked immunoglobulin is usually IgA, which is preferentially produced whenantigen exposure occurs by the wayof the gastrointestinal tract ( 1 ) . According to the antigen-driven theory, self-amylase can become immunogenic by cross-reacting with antibodies initially formed against foreign antigens, such as non-humanamylase (1). Since IgA is involved in all the cases with macroamylasemia associated with macrolipasemia as discussed above, the antigen-driven theory may also account for the formation of antibodies against lipase in these cases. Another possibility is that the immunoglobulin-enzyme complex formation is not due to a specific antigen-antibody reaction, as described previously (12) . Accumulation of cases with simultaneous macroamylasemiaand macrolipasemia will reveal the mechanismresponsible for such a unique immunoglobulin production.
Hasselbacher et al (13) reported that macroamylase was found in 25%of unselected patients with SLE, although linked immunoglobulins were not analyzed. There was no correlation between the presence of macroamylaseand the disease activity in their patients as in our patient. Considering SLE as a disease characterized by a host of autoantibodies, they suggested the possibility that antibodies to many different serum enzymes are frequent in SLE. Our case may be such an example. Further investigation is needed to clarify the frequency of the simultaneous presence of macroamylaseand other macroenzymes in patients with SLE.
In conclusion, clinicians must consider the simultaneous presence of macroenzymesas a rare cause in the differential diagnosis of elevated serum amylase and lipase activities.
